ClinicalTrials.gg
TerminatedNCT05219370Updated Apr 25, 2023

Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD

A Phase 2 interventional study of Cannabis oil in ADHD, Hyperactivity and Attention Deficit, sponsored by Brlev Agricultural Crops Ltd. Terminated at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-25.

Sponsored by Brlev Agricultural Crops Ltd · Phase 2, Interventional, and Treatment

Why this study was terminated
Difficulties in enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Israel — 9 open to participants now, 10 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Israel.

Enrollment
60th of 61
8 · median 46
Started
2022
with 3 others
Phase 2
10 of 85
1 open now
Registered
68th of 85
by date

Among the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Israel, this one is the 60th largest by enrollment of the 61 interventional ones that give a count, is one of 4 that started in 2022, is one of 10 in phase 2, and was the 68th registered.

Attention Deficit Disorder with Hyperactivity

1,818 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

9 of the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Israel are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Israel, or all of them as a file.
02

Study summary

ADHD is the most frequent neuro-developmental disorder in childhood and often continues into adolescence and adulthood.

Indicated drug treatments for ADHD fall into 2 categories: stimulants (such as methylphenidate and amphetamines) and non-stimulants (such as atomoxetine, guanfacine and clonidine) but some persons cannot tolerate their secondary effects or find them non-effective.

In the last decade, medical cannabis products have been researched as possible treatment for neurological and mental diseases such as: Post trauma disorder (PTD), autism (ASD), epilepsy, fibromyalgia (FM) and more.

Data on the effects of cannabidiol rich cannabis extract use for ADHD seems promising but is still limited. The aim of this study is to investigate if oral cannabinoids given to adults with ADHD affect the symptoms of the disorder.

The main objectives of the study are: 1) to characterize the effects of treatment with cannabis oil on symptoms of ADHD; 2) to compare safety and efficacy of cannabis oil products with different CBD,Cannabidivarin (CBDV), cannabigerol (CBG) and THC ratio; 3) and to measure endocannabinoids, THC and CBD and metabolites levels in the blood of the participants.

In this study, participants diagnosed with ADHD will be treated with canabidiol-rich cannabis oil and will follow up weekly during approx.1 month (the study period). Blood tests will be performed before and after treatment. Blood tests include blood count, blood chemistry, hormones profile, phyto- and endo- cannabinoids and their metabolites. Test of Variables of Attention test (TOVA) will be administrated before and after treatment

Read the detailed description

Participants will be screened by study staff for ADHD diagnosis and failure of conventional treatment.

Participants passing the screening will undergo blood and urine tests, fill questionnaires, TOVA test and will be randomized to one of the 4 arms.

Participants will receive the drug, be instructed as per dose titration and as per danger of driving under drug influence.

Telephone follow up will take place weekly after 7 days from starting. Participants will guess to which arm the participant was allocated to after 2 weeks of treatment .

Participants will arrive for a last visit, fill questionnaires, do TOVA test and undergo blood and urine tests.

Participants will be contacted over the phone for a last time, after treatment completion.

03

Conditions studied

  • ADHD
  • Hyperactivity
  • Attention Deficit

Keywords

  • medical cannabis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged at least 18 y/o diagnosed with ADHD by (DSM)
  • Participants with a lower than 0 TOVA score or with a higher than 0 score whom as per investigator opinion suffer from ADHD
  • Participants who experienced treatment failure with more than one ADHD conventional drug
  • Participants willing to attend all the visits in the trial.

Exclusion criteria

Exclusion Criteria:

  • Participants who were treated with benzodiazepines, antihistamines, etc, in the week that preceded the trial start.
  • Participants suffering from neurologic or psychiatric diseases
  • Participants suffering from malignant diseases
  • Participants suffering from syndromes or metabolic diseases
  • Participants with significant clinical diagnosis that can damage the trial unfolding. The investigator may include them after the end of the situation which prevented their previous inclusion.
  • Participants breastfeeding, pregnant or not willing to use .
  • Participants that will not adhere to the protocol as per investigator opinion
  • Participants who weight less than 45 kg or more than 120kg or with greater than 30
  • Participants participating in another clinical trial which includes drug treatment
  • Participants receiving any treatment for ADHD
  • Participants using drugs
  • Participants using cannabis or products containing cannabinoids, including medical cannabis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    CBD rich

    Cannabis oil oral drops containing 95 mg/ml CBD; 5 mg/ml THC; 15 mg/ml CBDV ; no CBG, once daily Titration from 0.3 to 1.8 ml/day during 21 days

    Drug: Cannabis oil

  • Experimental
    CBG rich

    Cannabis oil oral drops containing no CBD; 5 mg/ml THC; no CBDV; 95 mg/ml CBG, once daily. Titration from 0.3 to 1.8 ml/day during 21 days

    Drug: Cannabis oil

  • Experimental
    CBD & CBG rich

    Cannabis oil oral drops containing 47.5 mg/ml CBD; 2.5 mg/ml THC; 7.5 mg/ml CBDV; 47.5 mg/ml CBG, once daily. Titration from 0.3 to 1.8 ml/day during 21 days

    Drug: Cannabis oil

  • Placebo comparator
    placebo

    Placebo oil oral drops once daily. Titration from 0.3 to 1.8 ml/day during 21 days

    Drug: Cannabis oil

Interventions

  • administration of different cannabis oil types as compared with placebo

06

What researchers measure

Primary outcomes

  1. efficacy of cannabis oil on ADHD symptoms as per TOVA test

    To assess if participants treated with cannabis oil show an improvement in TOVA scores

    Time frame: 30-35 days

  2. efficacy of cannabis oil on ADHD symptoms as per Conners questionnaire

    To assess if participants treated with cannabis oil show an improvement in Conners score

    Time frame: 30-35 days

Secondary outcomes

  1. to assess side effects and their severity using questionnaire

    To examine whether cannabis oil side effects are tolerable and transient

    Time frame: 60 days

  2. number of participants who dropped-out

    to check whether drop out percentage is similar among groups

    Time frame: 60 days

07

Study locations

1 site
  • Shamir (Assaf Harofeh) Medical Center
    Be'er Ya'aqov, Israel
08

References and documents

Publications

  • Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015 Apr;135(4):e994-1001. doi: 10.1542/peds.2014-3482. Epub 2015 Mar 2. PubMed 25733754 ↗
  • Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur Neuropsychopharmacol. 2017 Aug;27(8):795-808. doi: 10.1016/j.euroneuro.2017.05.005. Epub 2017 May 30. PubMed 28576350 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study protocol and Statistical Analysis Plan to be shared

Supporting information: Study protocol, Statistical analysis plan

Time frame: during all the trial

Access criteria: interested colleagues

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Dec 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2021
First posted
Feb 2, 2022
StartActual
Jul 31, 2022
Primary completionActual
Dec 31, 2022
CompletionActual
Dec 31, 2022
Last update
Apr 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05219370
Lead sponsor
Brlev Agricultural Crops Ltd
Collaborators
Bio-Sciences Pharma Ltd.
Responsible party
Sponsor
First posted
Feb 2, 2022
Start date
Jul 31, 2022
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022
Last update
Apr 25, 2023

Study contacts

Mati Berkovitch
principal investigator · Shamir (Assaf Harofeh) Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabis sativa flowering TOP

Start the discussion